Call Us for Support
+91 9654860915
Finding access to medicine unapproved in your home country can feel overwhelming. We’re here to help you navigate the process, from your initial request to procurement coordination.
Submit your details and prescription to get started.Register today to get started on your medicine access journey.
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Order Voraxaze on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
BTG International Inc. (a SERB company)
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Voraxaze (glucarpidase) is an emergency antidote for methotrexate toxicity. High-dose methotrexate is used for cancers such as osteosarcoma, leukaemia and lymphoma, and it leaves the body through the kidneys. If the kidneys are not working well, methotrexate can stay at toxic levels in the blood.
In the United States, Voraxaze is approved for adults and children whose plasma methotrexate level is toxic (above 1 micromole per litre) and whose clearance is delayed because of impaired kidney function. In the European Union it is approved for adults and children aged 28 days and older with delayed methotrexate elimination or at risk of methotrexate toxicity. It is not used when methotrexate is clearing normally, because lowering the level too much could make the cancer treatment less effective. See our oncology medicines.
Glucarpidase is an enzyme. In the bloodstream it breaks methotrexate into inactive pieces, giving the body a way to get rid of methotrexate that does not depend on the kidneys.
In the main study, 22 patients with toxic methotrexate levels and kidney problems received Voraxaze. In 10 of them (45%), the methotrexate level fell to 1 micromole per litre or less within 15 minutes and stayed there for up to 8 days. Half of the patients in this group had osteosarcoma, and most of the rest had leukaemia or lymphoma.
The dose is 50 units per kg of body weight, given once as an intravenous injection over 5 minutes. Leucovorin rescue continues, but it must be given at least 2 hours before or after Voraxaze. For the first 48 hours the same leucovorin dose is kept; after that it is adjusted to the measured methotrexate level. Fluids and urine alkalinisation also continue as the doctor directs.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Serious hypersensitivity reactions occurred in less than 1% of patients. The care team watches for flushing, rash, breathing difficulty and low blood pressure during and after the injection.
After Voraxaze, an inactive breakdown product of methotrexate (DAMPA) makes standard immunoassay tests show falsely high methotrexate levels for up to 48 hours. During this time, methotrexate should be measured with a chromatographic method. This matters because leucovorin doses are based on these results.
Voraxaze is given together with ongoing care: the label says leucovorin rescue continues, along with fluids and urine alkalinisation as needed, guided by methotrexate levels.
Side effects linked to Voraxaze itself were uncommon: tingling or numbness, flushing, nausea or vomiting, low blood pressure and headache were each reported in more than 1% of patients. Other problems seen in these patients are usually caused by the methotrexate toxicity itself.
There is no information on Voraxaze in pregnancy or breastfeeding. It is always given with methotrexate, whose own strict pregnancy rules apply.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Voraxaze is not sold in India, so it is imported for one named patient. Because it is an emergency antidote, we treat every Voraxaze request as urgent.
As soon as the treating team sees delayed methotrexate clearance with kidney impairment, the doctor or family should call or WhatsApp us. We start the paperwork the same day.
We need the prescription with the patient's weight and the number of 1,000-unit vials (for example, a 40 kg patient needs 2,000 units, which is two vials), the latest methotrexate level and kidney test, and the patient's ID.
The Voraxaze price in India is quoted for the vials needed, plus urgent cold-chain freight and customs clearance.
We prepare the Form 12A application to CDSCO under Rule 36 of the Drugs and Cosmetics Rules. CDSCO states the Form 12B permit is usually issued within one to two days and stays valid for six months.
The vials travel at 2°C to 8°C with a temperature logger, on the fastest available route.
We deliver straight to the treating hospital pharmacy.
We cannot promise a fixed time. The permit usually takes one to two working days once documents are complete, and the flight depends on stock at source. The treating team should continue leucovorin, fluids and kidney support and not wait for the antidote. We tell you the expected arrival time with the quote.
No. Voraxaze (glucarpidase) has no marketing approval in India and is not sold in Indian pharmacies. We checked the published minutes of CDSCO's oncology and haematology expert committees from 2018 to November 2026, and glucarpidase does not appear in them. It can still be imported legally for a named patient under Rule 36, with a Form 12A application and a Form 12B permit.
Each vial contains 1,000 units of glucarpidase powder. The dose is 50 units/kg, so the number of vials depends on weight: 1 vial covers up to 20 kg, 2 vials up to 40 kg, and so on. People often search for the glucarpidase price, but the cost depends on the number of vials.
No. It is a hospital emergency medicine and cannot be sold off the shelf. The legal way is to send the prescription to NPP, and we arrange the permit and import in the patient's name.
Patients from Nepal, Bangladesh, Bhutan, Sri Lanka and the Gulf can also ask us, subject to each country's import rules. Read our guide to Indian import regulations for the full legal process.
Voraxaze is supplied by BTG International, a SERB company. As a Voraxaze supplier in India under the named patient route, NPP buys it only through authorised channels and only after the patient's permit is issued, so every vial can be traced to one patient and one prescription.
Vials must be kept in a refrigerator at 2°C to 8°C and must not be frozen. We ship in validated insulated boxes with a data logger and check the temperature record on arrival. Read more about our temperature-controlled shipping.
The hospital pharmacy dissolves each vial in 1 mL of saline, without shaking, and gives it as a 5-minute injection, flushing the line before and after.
A registered pharmacist matches every order with the prescription and the permit before it leaves New Delhi.
For the Voraxaze cost in India and current availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Voraxaze is given in hospital, usually in oncology wards that use high-dose methotrexate, so we deliver straight to the treating hospital by the fastest cold-chain route.
See how we arrange delivery of imported medicines to hospitals across India.
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message